19 8 1970 20 10 4 1



Similar documents
untitled

.H...A.....M.[00.\...\01.^.O.Z

日本皮膚科学会雑誌第121巻第11号

437“ƒ



untitled

_.L.O...z.W


jcvp試験問題HP.indd

ÿþ

第14〜15回 T細胞を介する免疫系.pptx



2 (1) (2) SCI 2 SCI

) km 200 m ) ) ) ) ) ) ) kg kg ) 017 x y x 2 y 5x 5 y )

CAR-T実施

1 Q A 82% 89% 88% 82% 88% 82%


土地改良523号.indd

0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2


ŁRُ•ñŁŁŁ‘


表1.eps

H26分子遺伝-20(サイトカイン).ppt

1) Urlne analysls 7)Serologlcal exam. 1 1)ECG W.N.L. sugar 0% CRP (-) urobillnogen N(+) RA (+) 12)Renal function albumin 3(+) ASLO (-) PSP test 15' 40




日本皮膚科学会雑誌第120巻第5号

BAANs理論に基づく保健指導プログラム暫定版

10中西_他.indd


日本皮膚科学会雑誌第122巻第2号

et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology

L

C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %

住まい・まちづくり活動事例集

Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS

(a) (b) (c) (d) 1: (a) (b) (c) (d) (a) (b) (c) 2: (a) (b) (c) 1(b) [1 10] 1 degree k n(k) walk path 4



5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU

からだにeヘルシーレシピ 高血圧

Taro10-名張1審無罪判決.PDF

WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH

日本目録規則1987年版改訂2版第2章図書改定案

d-00

終末期の呼吸困難症状への対応*松坂最終修正

日本皮膚科学会第121巻第9号

09 P107〜118/木下 〃 芦塚 〃 稲

コロイド化学と界面化学


Taro13-芦北(改).jtd

本文/AY380J



Taro13-宇城(改).jtd

無印良品 2012 自転車 カタログ

›Ê”÷„¤‰ƒ‘−…j…–†[…X

抗アレルギー効果のあるKW乳酸菌の発見と活用

ha ha km2 15cm 5 8ha 30km2 8ha 30km2 4 14



_1203new

Transcription:

19 8 1970 20 10 4 1

IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2

30 IgE 2. 3

1. B IgE T IgE IgE IgE 2 T IgE B IgE Th2 IgE Th1 Th1 Th2 Th1 IgE Th2 B IgE IL-4 T IL-12 Th2 Th1 IL-4, IL-13 IL-5, IL-10 IFN IL-2 IgE IgE B IgE IL-X = X 4 3. Th1 Th2 Th1 Th1 20 Th1 IgE Th2 1g 30 g B IgE IgE IgG 10 Th2 4 B IgE IgG IgA Th1 B IgE 2. IgE IgE 4

5 IgE IgE IgE 3. 1 Coombs 5 IgE IgE 4 Th2 B 6-24 10 T IgE 6

50% 5% 10% 10 Th2 Th2 4 5 5 10 6-24 10 6-24 IgE T T 7 8 4 4 Th2 Th2 4 5 6

1. IgE 1996 IgE IgE IgG IgE IgE IgG IgE IgE IgE IgE IgE IgE 9 IgE 10 IgE IgE RAST (radio-allergo-solvent test) IgE IgE CAP-FEIA Alastat LUMIWARD Mast CAP 7

RAST 3 LUMIWARD CAP-FEIA MAST IgE IgE IgE IgE 1 15 2 2 1 15mm 5mm IgE IgE (C5a) Th2 (fmlp) CC (MCP-3 ) 3 & 5 11 15 6 48 24-48 8 12

1-10ng/ml CAP-FEIA 90% - 2. IgE IgE IgE 6 2,3 IgE IgE ECP IgE IgE IgE ECP (eosinophil cationic protein) ECP ECP ECP 13 ECP 9

1. 0.2-0.5mm 8 1 25 Der 1 4 Der 1) 14 15 1g 23.25 g Der 1 1g 9.46 g 1g 1.97 g 1g Der 1 2 g IgE 10 g 1 0.05ml 0.1ml 0.2ml 0.3ml 0.4ml 0.5ml 1000 0.05ml 0.1ml 0.2ml 0.3ml 0.4ml 0.5ml 50% IgG IgE Th1 2. T IgE 10

B IgE 11

12 20 T Th1 16 17

1. 20 mg/ml 1 mg/ml 13

2. 3. IgE 90% IgE IgE 70% 6% IgE A B C IgE 19 18 IgE B C IgE 14

100% 90% 80% 70% 15 1 3 6 24 20 10 20-30 1-3 6-24 T 5 major basic protein (MBP) eosinophil cationic protein (ECP) 2 P A 15

5 IgE 4. 90% 5 T T Th2 4 5 4 IgE 5 5 T IgE IgE T T 5 Th2 24-48 5 A2 Th2 Th2 5 22 21 IgE 5 16

T 2-3 40 2-3 IgE 3 4 7 8 RS 85 20 2 cm 100 100 RS ICAM-1 ICAM-1 RS ICAM-1 ICAM-1 12 17 Mossad SB. Br. Med. J. 317:33, 1998 23 20

9 10 9 10 9 10 9 10 5. IgE IgE RS RS 3 IgE 5 IgG2 IgG2 2 IgG2 cystic fibrosis 6. 1 PEF 18

1 1 2 1 2 15 1 1997 NIH 1 12 200ml 2 2-3 1 1 20% 1 1998 T Th2 7. 19

IgE IgE Der 1 1g Der 1) Der 1) g/g 100 10 1 0.1 IgE IgE Nishioka K, JACI 1998 24 25 IgE IgE IgE 1 IgE 20

2-3 3 RS 3 IgE 2 2,3 IgE RS IgE IgE 2 1 21

Der 1 1g 2 g IgE 10 g 9 6-8 9 10% ACTH (NK) 22

8. 20 3 8 20 IgE 20 ECP T 4 5 23

10 1990 BDP BDP 400 g 5cm 4cm 4cm T ATP AMP 5 -AMP A 26 27 1 6 24 T 10 1 24

20 200-300 g BDP 4-6 2 AMP AMP (5-20 g/ml) 2 2 AMP 25

26

2 1 1 RS RS IgE 85% 2 2 14 3 1 27

28 70 6 28 RS 29 RS

90 10-20 3 RS 3 RS ICAM-1 ICAM-1 IgE 7 T (Th2 ) Th1 2 4 10 Th1 Th2 9. 90 1 29

30 6 10 1 T 1 T B 1 36.5 38 30

3 90% 20 40 31

1. 1997 20% 10% 37 30 5% 2% 1977 Hanifin 32

1994 Hanifin IgE 2 6 3 IgE IgE IgE IgE T T IgE IgE 31. 32. 33

2. T T T IgE T Th1 Th1 IgG2 33. 34

Th1 3. IgE IgE IgE IgE IgE Th1 IgE Th2 20% T IgE IgE T IgE IgE IgE 1-2 35

IgE IgE IgE IgE 4. IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE 1 cm 5. 2 36

37 95% Th1 Th2 IgE IgE IgE IgE T 35. T IgE T

5 T 38

A. B. B 39

2g 20g 2 15 6. 2,3 7,8 IgE IgE IgE 4 40

37. T T IgE IgE IgE 1 5,000 5 5,000 4,5 IgE 1-3 41

IgE IgE IgE IgE 7. 1) 1,1 IgE IgE IgE P P IgE 42

P IgE 80 2) IgE T T 43

44 1. IgE 1 7% 25% 2% 8% IgE

IgE 2. 1 100 IgE 30% IgE IgE 2,3 IgE 3. IgE 45

IgE Sampson IgE CAP-FEIA IgE 2-9kU/ml 90% 65kU/ml IgE IgE 3 1 4. 3 3 46

1-2 IgE 3 IgE IgE 5,000 Hong IgE T T Th1 Th2 Th1, Th2 47

1. IgE 2. 1960 1960-70 1960 1964 1970 48

eotaxin 1000 49

IgE 25 30% 70% 10 IgE 10,000IU/ml 1 IgE IgE 1 IgE 30 IgE IgE IgE 80 60 IgE / 40 2050 80 DNA RNA mrna 20 60 2000 40 20 39 2000 2050 IgE 40 DNA RNA mrna 13 13 3 13 mrna 6 13 mrna mrna RNA mrna 50

mrna mrna IgE TTACCCA TTAGCCA GeneChip, 1.2 cm 2 1 50 6800 mrna 42 DNA GeneChip) http://www.affymetrix.com/technology/index.html 41 Affymetrix DNA GeneChip 1.2cm 6,800 20 DNA CAGAGCTTG CAGTGCTTG CAGAGCTTG CAGTGCTTG GTCTCGAAT GTCACGAAT GTCTCGAAT GTCACGAAT CAGAGCUUG mrna CAGUGCUUG CAGAGCUUG CAGUGCUUG CCR5 SNP 43 SNP 44 SNP DNA 2000 mrna DNA 1% 1% 2,3 DNA DNA DNA 4 (single nucleotide polymorphism 51

SNP: ) 1 SNP SNP SNP 21 DNA 10 SNP: A SNP: B 45 52

SNP IgE IgE = Th1 IL-4, IL-13 IL-5, IL-10 Th2 Th2 IgE Th1 T IL-12 IFN B IgE Th2 Th1 IL-2 IL-X = X 47. DNA Th1 46 SNP CpG DNA Th1 Th1 Th1 CpG CpG CpG Th1 Th2 DNA DNA mrna 53

90% cystic fibrosis SNP 20 1 cystic fibrosis 30 SNP SNP SNP SNP SNP SNP 54

1999 12 50 2,3 1 1978 55

1. T 1923 Coca IgG IgE 5,000 18 58 180 IgE 1966 IgE IgE 100 IgG IgE IgE 2. DNA 3. 1. B IgE 5% T T Thymus T T T T Th1 Th2 56

B Bursa B 1 B T IgE IgG Th1 Th2 2 T 1 Th1 2 Th2 Th2 4 10 Th1 Th1 12 Th2 100 IgE Th1 Th2 B B antigen antibody B IgG, IgA, IgM, IgE 4 IgG 1ml 13mg IgE 1ml 0.01mg Th2 B B B 4 13 IgE VCAM-1 Th1 B IgE T IgG IgG2 Th1 12 12 DNA CpG 2. IgE IgE Coombs Coombs Gell 1963 IgE IgE 57

IgG IgM SLE T 48 A2 C4, D4 C4 D4 3. Th2 Th1 Coombs 3 3 5 GM-CSF 10 1 6 IgG IgM 3 5 T B T T Th1 Th2 T T T B T 58

Th2 ECP C4 3 GM-CSF 1. 1-3 IgG IgE 0.5% IgE 2 2. 1. 2. C4 B4 PAF 1 CC CXC CC eotaxin TNF 1 ICAM-1 4 13 VCAM-1 ICAM-1 VCAM-1 59

DNA mrna 1. 2. 3. major basic protein (MBP) eosinophil cationic protein (ECP) P A 4. 6 IgG2 IgG 4 IgG2 IgA IgE 2 ICAM-1 1 TNF 20-30nm RNA 9 10 100 RS 150-300nm 60

3 5. 6. 1 1 1 1 2 1 2 1 2 1 2 2 1 7. 2 AMP AMP Der 1 IgE Der 1 (1-10 ) Der p 1 Der f 1 Der 1 2 2 ACTH 61

ACTH (NK) 12 Th1 0.9%NaCl 8. AMP 2 ATP AMP AMP A AMP AMP AMP DNA 9. 1. 2. 62

IgE T T T 0.01% T 20% Th1 IgE Th2 IgE IgE Coombs T Th1 12 3. 4. 5. T T 63

1980 A FK506 FK506 6. 7. 1) IgE IgE IgE IgE IgE IgE IgE IgE B T DNA SLE, 2) 1. B Gad c 1 IgE Gad c 1 IgE Gad c 1 2. 3. 4. 1. 2. Eotaxin MCP-1, RANTES MIP-1 CC. 4 DNA DNA A T G C A T G C DNA 60 10 mrna 64

RNA mrna DNA RNA mrna T U 64 20 mrna 20 4 3 DNA RNA G C C G A U T A mrna mrna DNA mrna 3 64 20 mrna 1 =1 DNA mrna transcription DNA 1.2cm 20 Affimetrix GeneChip cdna mrna Stanford cdna DNA mrna DNA SNP DNA mrna DNA mrna mrna mrna DNA DNA RNA DNA A T G C 4 RNA U A T(U), G C 6-8 65

IgE Nakagomi T, et al. Lancet 343: 121,1994. Erb KJ. Immunol. Today. 21:317-321,1999. Barnes KC, Marsh DG. Immunol. Today 19: 325, 1998. 3: 27, 1999. Greenberg RA et al. J. Pediatr. 114: 774, 1989. Murray AB et al. J. Allergy Clin. Immunol. 91: 102, 1993. Sporik R. et al. N. Eng. J. Med. 323:502, 1990. Kivity S et al. J Allergy Clin Immunol 91:844,1993. Platts-Mills TAE et al. Lancet 2:675,1982. Arshad SH et al. Lancet 339:1493, 1992. Nishioka K, et al. J. Allergy Clin. Immunol. 101:28, 1998. Iikura Y, et al. Ann. Allergy 68:233, 1992. Pedesen S, et al. Eur. Respir. J. 12:30, 1998. Sheffer AL et al. J Allergy Clin Immunol 88:425,1991. 1998 Wolthers OD et al. Pediatr 1992;89:839. Barnes PJ Am Rev Respir Dis 1993; 48: 511. Busse WW. Am. J. Respir. Crit. Care Med. 151: 1675, 1995. Johnston SL: Clin. Exp. Allergy 1996; 26:989. Mossad SB. Br. Med. J. 317:33, 1998. KK 1994 Kraneveld AD, et al. Am. J. Respir. Crit. Care Med. 156:367,1997 Yasui K, et al. J. Clin. Invest. 100:1677,1997. Shichijo M, et al. J. Allergy Clin. Immunol. 103:421,1999. 1988 1995 : 1993;38:44 Nomura I, et al. J. Allergy Clin. Immunol. 104:441,1999. Th1 Th2 66

Grewe M et al.: Lancet. 343:25,1994 Sampson HA. J. Allergy Clin. Immunol. 103:717, 1999. Shicerer SH, Sampson HA. J. Allergy Clin. Immunol. 104:114, 1999. Hong SJ, et al. J. Allergy Clin. Immunol. 104:473,1999. Eotaxin Mochizuki M et al. J. Immunol. 160:60,1998 Fukagawa K, et al. J. Allergy Clin. Immunol. 103:1220, 1999. CpG Klinman DM, et al. Immunity 11:123, 1999 Hartmann G, et al. Proc. Natl. Acad. Sci. USA 96,9305, 1999. Chanock SJ, Foster CB. J. Clin. Invest. 104:369-370,1999 Silver LM. 1999 Reiss M, Straughan R ( ): 1999 DNA http://www.affymetrix.com/technology/index.html http://www.synteni.com/products/arrays/technology.html 67